Fan et al. demonstrated the selective action of Berberine against Gefitinib-resistant NSCLC cell lines H1975 and H1650, by modulating the ROS/AMPK pathway to suppress sterol regulatory element-binding protein 1 (SREBP-1) and lipogenesis, thus inhibiting cancer cell proliferation [108]. The gene discussed is SREBF1; the disease is non-small cell lung carcinoma.